





All Patients (n=537)
MPC: 5%; Control: 13%
Rexlemestrocel Effect Size: 60%
p=0.002

FIGURE 1


A



NYHA II
MPC: 6%; Control: 14%
Rexlemestrocel Effect Size: 57%
p=0.05

FIGURE 2-1


B



NYHA III
MPC: 4%; Control: 12%
Rextemestrocel Effect Size: 67%
p=0.014

FIGURE 2-2


A



Ischemic Patients (n=303)
MPC: 6.6%; Control: 17%
Rexlemestrocel Effect Size: 61%
p=0.007

FIGURE 3-1

B



Non-Ischemic Patients (n=234)
MPC: 2.7%; Control: 8.1%
Rexlemestrocel Effect Size: 66%
p=0.08

FIGURE 3-2

A




FIGURE 4-1

B




FIGURE 4-2

C





FIGURE 4-3

D

Patient Groups	Total # Pts.	MPC				CTRL				Forest Plots	Risk ↓ due to MPCs	Rate Ratio	95% CI	P-Value
		# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u	# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u					
All treated patients	537	261	44	632	6.966	276	55	709	7.760		NA	0.898	0.604, 1.334	0.593
NYHA Class II	206	100	8	286	2.802	106	21	314	6.689		58%	0.419	0.186, 0.946	0.036
NYHA Class III	331	161	36	346	10.401	170	34	395	8.613		NA	1.208	0.756, 1.930	0.430

FIGURE 4-4


A



NYHA II Ischemic (n=111)
MPC: 10.7%; Control: 21.8%
Rexlemestrocel Effect Size: 51%
p=0.251

FIGURE 5-1

B



NYHA II Non-Ischemic (n=95)
MPC: 4.5%; Control: 17.6%
Rexlemestrocel Effect Size: 74%
p=0.06

FIGURE 5-2




FIGURE 6

A




FIGURE 7-1

B

Rate Normalized for Follow-up Time (Events Per 100 Pt-Years)	Total # Pts.	MPC				CTRL				Forest Plots	Risk ↓ due to MPCs	HR	95% CI	P-Value	
		# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u	# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u						
Composite IMIM MACE: Recurrent Non-fatal MI or Recurrent Non-fatal Stroke or Cardiovascular Death															
All treated patients	537	261	57	632	9.024	276	99	709	13.968		35%	0.646	0.446, 0.895	0.009	
BL hsCRP ≥2 mg/L	301	153	30	360	8.339	148	59	352	16.767		50%	0.497	0.320, 0.772	0.002	

0.1250.250.51.02.0

MPC BetterControl Better

FIGURE 7-2

C




FIGURE 7-3

D




FIGURE 7-4

E




FIGURE 7-5

F




FIGURE 7-6

A




FIGURE 8-1

B

Rate Normalized for Follow-up Time (Events Per 100 Pt-Years)	Total # Pts.	MPC			CTRL			Forest Plots	Risk ↓ due to MPCs	HR	95% CI	P-value	
		# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u	# Pts.	# Events						Person Yrs f/u
Composite IMM MACE: Recurrent Non-fatal MI or Recurrent Non-fatal Stroke or Cardiovascular Death													
All treated patients	537	261	12	632	1.900	276	44	709	6.208		0.306	0.162, 0.579	<0.001
BL hsCRP ≥2 mg/L	301	153	4	360	1.112	148	23	352	6.536		0.170	0.059, 0.492	0.001
NYHA Class II	206	100	5	286	1.751	106	19	314	6.052		0.289	0.108, 0.775	0.014
Class II + BLhsCRP ≥2 mg/L	97	49	1	145	0.690	48	8	125	6.419		0.107	0.013, 0.859	0.035
NYHA Class III	331	161	7	346	2.022	170	25	395	6.333		0.319	0.138, 0.738	0.008
Class III + BLhsCRP ≥2 mg/L	204	104	3	215	1.397	100	15	227	6.601		0.212	0.061, 0.731	0.014

0.1250.250.51.02.0

MPC BetterControl Better

FIGURE 8-2

C




FIGURE 8-3

D




FIGURE 8-4

F




FIGURE 8-5

F




FIGURE 8-6

A




FIGURE 9-1

B




FIGURE 9-2

C







FIGURE 9-3

D

Patient Groups	Total # Pts.	MPC				CTRL				Forest Plots	Risk ↓ due to MPCs	Rate Ratio	95% CI	P-Value
		# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u	# Pts.	# Events	Person Yrs f/u	Events Per 100 Yrs f/u					
All treated patients	537	261	57	632	9.024	276	99	709	13.968		35%	0.646	0.456, 0.895	0.009
NYHA Class II	206	100	14	286	4.903	106	40	314	12.740		61%	0.385	0.209, 0.707	0.002
NYHA Class III	331	161	43	346	12.423	170	59	395	14.945		NA	0.831	0.561, 1.231	0.357





FIGURE 9-4



MPC NYHA II: 8%
MPC NYHA III: 22.3%
Saline NYHA II: 20%
Saline NYHA III: 20%
P=0.004

FIGURE 10

A




FIGURE 11-1

B




FIGURE 11-2

A




FIGURE 12-1

B




FIGURE 12-2




FIGURE 13

A




FIGURE 14-1

B




FIGURE 14-2

A




FIGURE 15-1

B




FIGURE 15-2

C




FIGURE 15-3




FIGURE 16




FIGURE 17




FIGURE 18